Multiple Sclerosis Clinical Trial
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Summary
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include:
This event-driven study will have variable duration ranging from approximately 27 to 51 months.
The study intervention duration will vary ranging from approximately 27 to 51 months.
The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
Eligibility Criteria
Inclusion Criteria:
Participant must have a previous diagnosis of RRMS in accordance with the 2017 revised McDonald criteria.
Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013 endorsed by an Adjudication Committee.
Participant must have documented evidence of disability progression observed during the 12 months before screening. Eligibility will be analyzed by an Adjudication Committee.
Absence of clinical relapses for at least 24 months.
The participant must have an EDSS score at screening from 3.0 to 6.5 points, inclusive.
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
The participant has a history of infection or may be at risk for infection.
The presence of psychiatric disturbance or substance abuse.
History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment.
History or current hypogammaglobulinemia.
A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren's syndrome, acute disseminated encephalomyelitis, and myasthenia gravis.
The participant has sensitivity to any of the study interventions, or components thereof, or has a drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
The participant was previously exposed to frexalimab.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 22 Locations for this study
Birmingham Alabama, 35209, United States
Carlsbad California, 92011, United States
West Hollywood California, 90048, United States
Clearwater Florida, 33761, United States
Maitland Florida, 32761, United States
Tampa Florida, 33609, United States
Overland Park Kansas, 66210, United States
Lutherville Maryland, 21093, United States
Wellesley Massachusetts, 02481, United States
Owosso Michigan, 48867, United States
Ozark Missouri, 65721, United States
Amherst New York, 14226, United States
Charlotte North Carolina, 28210, United States
Raleigh North Carolina, 27607, United States
Cincinnati Ohio, 45212, United States
Columbus Ohio, 43235, United States
Knoxville Tennessee, 37922, United States
Kogarah New South Wales, 2217, Australia
Heidelberg Victoria, 3084, Australia
Gatineau Quebec, J8Y 1, Canada
Levis Quebec, G6W0M, Canada
Quebec , G1J 1, Canada
How clear is this clinincal trial information?